IK
☆    

India,
2010-05-27 12:11
(5873 d 11:12 ago)

Posting: # 5383
Views: 4,326
 

 Buffer Addition for Stability of drug in Matrix [Bioanalytics]

Dear All,

In a Method Validation - Plasma Preparation has been done by adding 30ml of 25% Ascorbic acid solution in 100ml plasma (i.e. 30% buffer solution in plasma). All QC & CC standards prepared as mentioned above.

Whereas during sample collection (clinical phase) 50µL of 25% Ascorbic Acid has been added to vial containing approx. 1.5ml plasma.

From the above it is evident that the % buffer added to plasma during validation and sample collection do not mimic (more variation in % buffer).

With Reference to the above:
  1. Please comment on the affect of quantitation of the drug during analysis of the subject samples.
  2. Is it required to evaluate Long Term Stability with standards (QC standards) having similar concentraion of buffer as that of subject samples?
Kindly provide your comments at the earliest. Thanks in advance.

Best Regards
IK
Ohlbe
★★★

France,
2010-05-27 13:35
(5873 d 09:48 ago)

@ IK
Posting: # 5384
Views: 3,768
 

 Buffer Addition for Stability of drug in Matrix

Dear IK,

I would recommend a full revalidation of the method using the same conditions as for the subject samples, and to use for the study phase calibration and QC samples containing the same proportion of ascorbic acid as the subject samples.

Tons of reasons for this. There was a huge dilution of your samples during validation. This reduces the protein contents (which can influence recovery), the amount of matrix components (which can influence matrix effects), changes the pH due to ascorbic acid (recovery again), etc. Just look at the difference in response you can get between CPD plasma (approximately 20 % dilution due to the CPD buffer) and EDTA plasma !

In addition I would certainly repeat the long-term stability as you have a different amount of stabiliser (and a different pH).

Regards
Ohlbe

Regards
Ohlbe
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2010-05-27 16:22
(5873 d 07:01 ago)

@ IK
Posting: # 5385
Views: 3,662
 

 Matrix (validation # study)

Dear IK,

I agree with Ohlbe's post.
What was the rationale to 'validate' the method in a matrix different from the study's? Such a procedure is against all guidelines (FDA, EMA, ANVISA, ...).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
IK
☆    

India,
2010-05-28 10:01
(5872 d 13:22 ago)

@ Helmut
Posting: # 5391
Views: 3,553
 

 Matrix (validation # study)

Dear Ohlbe and HS,

Thanks a lot for your valuable comments.

Best Regards
IK


Edit: Full quote removed. Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2010-05-28 13:15
(5872 d 10:08 ago)

@ IK
Posting: # 5392
Views: 3,563
 

 Matrix (validation # study)

Dear IK,

THX for not answering my question.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
187 visitors (0 registered, 187 guests [including 63 identified bots]).
Forum time: 23:23 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5